JP2001527023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001527023A5 JP2001527023A5 JP2000506936A JP2000506936A JP2001527023A5 JP 2001527023 A5 JP2001527023 A5 JP 2001527023A5 JP 2000506936 A JP2000506936 A JP 2000506936A JP 2000506936 A JP2000506936 A JP 2000506936A JP 2001527023 A5 JP2001527023 A5 JP 2001527023A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- active
- active agent
- polymer
- stomach
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 description 47
- 239000003795 chemical substances by application Substances 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 17
- 210000002784 Stomach Anatomy 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 4
- 229960004023 Minocycline Drugs 0.000 description 4
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric Effects 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- 229940023040 Acyclovir Drugs 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 229960001058 Bupropion Drugs 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 229960002963 Ganciclovir Drugs 0.000 description 3
- 229960003105 Metformin Drugs 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 230000001430 anti-depressive Effects 0.000 description 3
- 230000003178 anti-diabetic Effects 0.000 description 3
- 230000000843 anti-fungal Effects 0.000 description 3
- 230000002058 anti-hyperglycaemic Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 230000000840 anti-viral Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002218 hypoglycaemic Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229960001380 Cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N Cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N Fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- CJCSPKMFHVPWAR-JTQLQIEISA-N Methyldopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 2
- 229960000615 Methyldopa Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 Ranitidine Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940083181 centrally acting adntiadrenergic agents Methyldopa Drugs 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 229920001888 polyacrylic acid Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 1
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229920001429 Chelating resin Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229960002900 Methylcellulose Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Chemical class 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000001078 anti-cholinergic Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 胃で保持するのに適合した活性剤剤形であって、(a)活性剤の治療学的有効量;(b)活性剤が分散または溶解されるポリマーマトリックスであり、そのポリマーマトリックスが膨潤可能な水溶性ポリマーとヒドロアトラクタントとを含み、そのポリマーマトリックスが使用環境に晒される外側表面を有するポリマーマトリックス;および、(c)そのポリマーマトリックスの表面の一部を封じ込める不溶性物質の少なくとも1本のバンドを含む活性剤剤形。
【請求項2】 水溶性ポリマーの数平均分子量が、約100,000〜20,000,000グラム/モルの間である、請求項1に記載の活性剤剤形。
【請求項3】 水溶性ポリマーが、ポリエチレンオキシド、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース、ナトリウムカルボキシメチルセルロース、カルシウムカルボキシメチルセルロース、メチルセルロース、ポリアクリル酸、モルトデキストリン、予めゼラチン化した澱粉またはポリビニルアルコールである、請求項2に記載の活性剤剤形。
【請求項4】 ヒドロアトラクタントが、低級置換ヒドロキシプロピルセルロース、微結晶セルロース、架橋されたナトリウムまたはカルシウムカルボキシメチルセルロース、セルロース繊維、架橋されたポリビニルピロリドン、架橋されたポリアクリル酸、架橋されたアンバーライト樹脂、アルギネート類、コロイドマグネシウム−アルミニウムシリケート、トウモロコシ澱粉顆粒、米澱粉顆粒、馬鈴薯澱粉顆粒またはナトリウムカルボキシメチル澱粉である、請求項3に記載の活性剤剤形。
【請求項5】 活性剤が、抗ウイルス剤、抗微生物剤、抗糖尿病剤、抗高血糖症剤、低血糖症剤、抗うつ剤、抗肥満症剤または抗真菌活性剤である、請求項4に記載の活性剤剤形。
【請求項6】 活性剤が、アシクロビル、ガンシクロビル、シメチジン、ラニチジン、カプトプリル、メチルドーパ、セレギリン、ミノサイクリン、メトフォルミン、ブプロピオン、オルスタットもしくはフェキソフェナジン、または、これらの薬学的に許容可能な塩である、請求項5に記載の活性剤剤形。
【請求項7】 ポリマーマトリックス内の水溶性ポリマーの重量パーセントが、約5〜90重量%であり、ポリマーマトリックス内のヒドロアトラクタントの重量パーセントが、約5〜60重量%である、請求項4に記載の活性剤剤形。
【請求項8】 剤形が、1回の適用量として、長時間にわたって、活性剤の治療学的に有効な量を胃に供給することに適合し、その剤形の相対的な吸収指数が少なくとも0.5である、請求項1に記載の活性剤剤形。
【請求項9】 長期時間が、少なくとも4時間である、請求項8に記載の活性剤剤形。
【請求項10】 その時間が約8〜12時間の間である、請求項9に記載の活性剤剤形。
【請求項11】 その相対的な吸収指数が少なくとも1.0である、請求項8に記載の活性剤剤形。
【請求項12】 胃で保持するのに適合した活性剤剤形であって、その物理的な一体性を長時間にわたって維持しつつ、胃内で膨潤する第1の部分を有するゲル形成浸食可能なポリマーマトリックス内の固体活性剤の単位圧縮分散系と、胃内でその剤形を長時間にわたって保持するのを促進するための第2の非浸食可能な非ゲル形成部分とを含む剤形。
【請求項13】 ポリマーが、数平均分子量少なくとも100,000グラム/モルを有するポリエチレンオキシドを含む、請求項12に記載の剤形。
【請求項14】 活性剤が、抗ウイルス剤、抗微生物剤、抗糖尿病剤、抗高血糖症剤、低血糖症剤、抗うつ剤、抗肥満症剤または抗真菌活性剤である、請求項13に記載の活性剤剤形。
【請求項15】 活性剤が、アシクロビル、ガンシクロビル、ミノサイクリン、シメチジン、ラニチジン、カプトプリル、メチルドーパ、セレギリン、ミノサイクリン、フェキソフェナジン、メトフォルミン、ブプロピオン、オーリスタット、または、これらの薬学的に許容可能な塩である、請求項14に記載の剤形。
【請求項16】 数平均分子量約100,000〜20,000,000グラム/モルを有するポリエチレンオキシドポリマー約5重量%〜約50重量%;および,ヒドロキシプロピルセルロースポリマーの約10重量%〜約13重量%のヒドロキシプロピル含量を有するヒドロキシプロピルセルロースポリマーの約5重量%〜約60重量%を含む組成物をポリマーマトリックス中に含む、請求項1〜15のいずれか1項に記載の活性剤剤形。
【請求項17】 胃で保持するのに適合した活性剤剤形であって、アシクロビル、ガンシクロビル、メトフォルミン、ブプロピオン、オーリスタットおよびミノサイクリンンならびに生物浸食可能なポリマーからなる群より選択される活性剤を含み、その剤形が、対象の胃に活性剤の治療学的に有効な量を少なくとも6時間にわたって放出する活性剤剤形。
【請求項18】 胃で保持するのに適合した活性剤剤形であって、剤形を投与する対象の胃に長時間にわたって活性剤を供給するのに適合した活性剤溜め;高分子量水溶性のポリマーを含むポリマーマトリックス;および、活性剤溜めに接続し、対象の胃内で流体と接触する時に膨張し、対象の胃内での剤形の保持を促進する水不溶性ハイドロアトラクタントを含む剤形。
【請求項19】 ポリマーマトリックスが、少なくともポリマーの一部を封じ込める不溶性物質の少なくとも1つのバンドを含む管状である、請求項18に記載の剤形。
【請求項20】 活性剤溜めからの活性剤の供給が浸透圧で推進される、請求項19に記載の剤形。
【請求項21】 供給される活性剤の相対的な吸収指数が少なくとも0.5となるような制御された速度で活性剤の治療学的に有効な量を供給するのに適合した胃内保持、生物浸食可能な活性剤剤形。
【請求項22】 活性剤が、抗ウイルス剤、抗生物質、抗糖尿病剤、抗高血糖症剤、低血糖症剤、抗うつ剤、抗肥満症剤または抗真菌活性剤である、請求項21に記載の活性剤剤形。
【請求項23】 相対的な吸収指数が1以上である、請求項22に記載の活性剤剤形。
【請求項24】 水溶性の膨潤可能なポリマー;および、活性剤の治療学的有効な量を対象の胃に持続性時間およびその生物当量供給するのに適合したヒドロアトラクタントを含む胃保持性、生物浸食可能な活性剤剤形。
【請求項25】 活性剤でその治療を必要とする対象を処置するための方法に使用する請求項1〜24のいずれか1項に記載の活性剤剤形であって、該方法が、各投薬時間の開始時に、活性剤を含み持続性保持時間にわたって活性剤の胃内保持および放出に適合した1つ以上の活性剤剤形をその対象に投与することを含む方法である、前記剤形。
【請求項26】 対象の胃内で膨潤するのに適合した胃内保持剤形を投与する方法に使用する請求項12〜24のいずれか1項に記載の活性剤剤形であって、該方法が、各投与時間の開始時に、対象に食物を供給する状態で、1つ以上の剤形を投与することを含む方法である、前記剤形。
【請求項27】 剤形の投与が、食物を消費した対象で1時間以内に生ずる、請求項26に記載の剤形。
【請求項28】 胃を空とする遅延剤を含む、請求項1に記載の剤形。
【請求項29】 胃を空にする遅延剤が、抗コリン作動薬、メチルセルロース、グアーガム、10〜15個の炭素原子を有する脂肪および脂肪酸類から選択される、請求項28に記載の剤形。
【請求項1】 胃で保持するのに適合した活性剤剤形であって、(a)活性剤の治療学的有効量;(b)活性剤が分散または溶解されるポリマーマトリックスであり、そのポリマーマトリックスが膨潤可能な水溶性ポリマーとヒドロアトラクタントとを含み、そのポリマーマトリックスが使用環境に晒される外側表面を有するポリマーマトリックス;および、(c)そのポリマーマトリックスの表面の一部を封じ込める不溶性物質の少なくとも1本のバンドを含む活性剤剤形。
【請求項2】 水溶性ポリマーの数平均分子量が、約100,000〜20,000,000グラム/モルの間である、請求項1に記載の活性剤剤形。
【請求項3】 水溶性ポリマーが、ポリエチレンオキシド、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース、ナトリウムカルボキシメチルセルロース、カルシウムカルボキシメチルセルロース、メチルセルロース、ポリアクリル酸、モルトデキストリン、予めゼラチン化した澱粉またはポリビニルアルコールである、請求項2に記載の活性剤剤形。
【請求項4】 ヒドロアトラクタントが、低級置換ヒドロキシプロピルセルロース、微結晶セルロース、架橋されたナトリウムまたはカルシウムカルボキシメチルセルロース、セルロース繊維、架橋されたポリビニルピロリドン、架橋されたポリアクリル酸、架橋されたアンバーライト樹脂、アルギネート類、コロイドマグネシウム−アルミニウムシリケート、トウモロコシ澱粉顆粒、米澱粉顆粒、馬鈴薯澱粉顆粒またはナトリウムカルボキシメチル澱粉である、請求項3に記載の活性剤剤形。
【請求項5】 活性剤が、抗ウイルス剤、抗微生物剤、抗糖尿病剤、抗高血糖症剤、低血糖症剤、抗うつ剤、抗肥満症剤または抗真菌活性剤である、請求項4に記載の活性剤剤形。
【請求項6】 活性剤が、アシクロビル、ガンシクロビル、シメチジン、ラニチジン、カプトプリル、メチルドーパ、セレギリン、ミノサイクリン、メトフォルミン、ブプロピオン、オルスタットもしくはフェキソフェナジン、または、これらの薬学的に許容可能な塩である、請求項5に記載の活性剤剤形。
【請求項7】 ポリマーマトリックス内の水溶性ポリマーの重量パーセントが、約5〜90重量%であり、ポリマーマトリックス内のヒドロアトラクタントの重量パーセントが、約5〜60重量%である、請求項4に記載の活性剤剤形。
【請求項8】 剤形が、1回の適用量として、長時間にわたって、活性剤の治療学的に有効な量を胃に供給することに適合し、その剤形の相対的な吸収指数が少なくとも0.5である、請求項1に記載の活性剤剤形。
【請求項9】 長期時間が、少なくとも4時間である、請求項8に記載の活性剤剤形。
【請求項10】 その時間が約8〜12時間の間である、請求項9に記載の活性剤剤形。
【請求項11】 その相対的な吸収指数が少なくとも1.0である、請求項8に記載の活性剤剤形。
【請求項12】 胃で保持するのに適合した活性剤剤形であって、その物理的な一体性を長時間にわたって維持しつつ、胃内で膨潤する第1の部分を有するゲル形成浸食可能なポリマーマトリックス内の固体活性剤の単位圧縮分散系と、胃内でその剤形を長時間にわたって保持するのを促進するための第2の非浸食可能な非ゲル形成部分とを含む剤形。
【請求項13】 ポリマーが、数平均分子量少なくとも100,000グラム/モルを有するポリエチレンオキシドを含む、請求項12に記載の剤形。
【請求項14】 活性剤が、抗ウイルス剤、抗微生物剤、抗糖尿病剤、抗高血糖症剤、低血糖症剤、抗うつ剤、抗肥満症剤または抗真菌活性剤である、請求項13に記載の活性剤剤形。
【請求項15】 活性剤が、アシクロビル、ガンシクロビル、ミノサイクリン、シメチジン、ラニチジン、カプトプリル、メチルドーパ、セレギリン、ミノサイクリン、フェキソフェナジン、メトフォルミン、ブプロピオン、オーリスタット、または、これらの薬学的に許容可能な塩である、請求項14に記載の剤形。
【請求項16】 数平均分子量約100,000〜20,000,000グラム/モルを有するポリエチレンオキシドポリマー約5重量%〜約50重量%;および,ヒドロキシプロピルセルロースポリマーの約10重量%〜約13重量%のヒドロキシプロピル含量を有するヒドロキシプロピルセルロースポリマーの約5重量%〜約60重量%を含む組成物をポリマーマトリックス中に含む、請求項1〜15のいずれか1項に記載の活性剤剤形。
【請求項17】 胃で保持するのに適合した活性剤剤形であって、アシクロビル、ガンシクロビル、メトフォルミン、ブプロピオン、オーリスタットおよびミノサイクリンンならびに生物浸食可能なポリマーからなる群より選択される活性剤を含み、その剤形が、対象の胃に活性剤の治療学的に有効な量を少なくとも6時間にわたって放出する活性剤剤形。
【請求項18】 胃で保持するのに適合した活性剤剤形であって、剤形を投与する対象の胃に長時間にわたって活性剤を供給するのに適合した活性剤溜め;高分子量水溶性のポリマーを含むポリマーマトリックス;および、活性剤溜めに接続し、対象の胃内で流体と接触する時に膨張し、対象の胃内での剤形の保持を促進する水不溶性ハイドロアトラクタントを含む剤形。
【請求項19】 ポリマーマトリックスが、少なくともポリマーの一部を封じ込める不溶性物質の少なくとも1つのバンドを含む管状である、請求項18に記載の剤形。
【請求項20】 活性剤溜めからの活性剤の供給が浸透圧で推進される、請求項19に記載の剤形。
【請求項21】 供給される活性剤の相対的な吸収指数が少なくとも0.5となるような制御された速度で活性剤の治療学的に有効な量を供給するのに適合した胃内保持、生物浸食可能な活性剤剤形。
【請求項22】 活性剤が、抗ウイルス剤、抗生物質、抗糖尿病剤、抗高血糖症剤、低血糖症剤、抗うつ剤、抗肥満症剤または抗真菌活性剤である、請求項21に記載の活性剤剤形。
【請求項23】 相対的な吸収指数が1以上である、請求項22に記載の活性剤剤形。
【請求項24】 水溶性の膨潤可能なポリマー;および、活性剤の治療学的有効な量を対象の胃に持続性時間およびその生物当量供給するのに適合したヒドロアトラクタントを含む胃保持性、生物浸食可能な活性剤剤形。
【請求項25】 活性剤でその治療を必要とする対象を処置するための方法に使用する請求項1〜24のいずれか1項に記載の活性剤剤形であって、該方法が、各投薬時間の開始時に、活性剤を含み持続性保持時間にわたって活性剤の胃内保持および放出に適合した1つ以上の活性剤剤形をその対象に投与することを含む方法である、前記剤形。
【請求項26】 対象の胃内で膨潤するのに適合した胃内保持剤形を投与する方法に使用する請求項12〜24のいずれか1項に記載の活性剤剤形であって、該方法が、各投与時間の開始時に、対象に食物を供給する状態で、1つ以上の剤形を投与することを含む方法である、前記剤形。
【請求項27】 剤形の投与が、食物を消費した対象で1時間以内に生ずる、請求項26に記載の剤形。
【請求項28】 胃を空とする遅延剤を含む、請求項1に記載の剤形。
【請求項29】 胃を空にする遅延剤が、抗コリン作動薬、メチルセルロース、グアーガム、10〜15個の炭素原子を有する脂肪および脂肪酸類から選択される、請求項28に記載の剤形。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5547597P | 1997-08-11 | 1997-08-11 | |
US60/055,475 | 1997-08-11 | ||
PCT/US1998/016597 WO1999007342A1 (en) | 1997-08-11 | 1998-08-10 | Prolonged release active agent dosage form adapted for gastric retention |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001527023A JP2001527023A (ja) | 2001-12-25 |
JP2001527023A5 true JP2001527023A5 (ja) | 2006-01-05 |
Family
ID=21998085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000506936A Pending JP2001527023A (ja) | 1997-08-11 | 1998-08-10 | 胃で保持するのに適合した長期放出性活性剤剤形 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6120803A (ja) |
EP (1) | EP1003476B1 (ja) |
JP (1) | JP2001527023A (ja) |
AT (1) | ATE285226T1 (ja) |
AU (1) | AU8699298A (ja) |
DE (1) | DE69828289T2 (ja) |
ES (1) | ES2234139T3 (ja) |
HK (1) | HK1028196A1 (ja) |
PT (1) | PT1003476E (ja) |
WO (1) | WO1999007342A1 (ja) |
Families Citing this family (235)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
US6251866B1 (en) | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
KR100514264B1 (ko) * | 1997-08-26 | 2005-09-15 | 아벤티스 파마슈티칼스 인크. | 피페리디노알칸올-충혈완화제 조합용 제약 조성물 |
EP2332522A3 (en) * | 1998-03-19 | 2011-12-07 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
EP1469009A2 (en) | 1998-05-21 | 2004-10-20 | Isis Parmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
JP2002524410A (ja) * | 1998-09-08 | 2002-08-06 | スミスクライン・ビーチャム・コーポレイション | リプスタチン誘導体−可溶性繊維錠剤 |
FR2784583B1 (fr) * | 1998-10-16 | 2002-01-25 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
US6706282B1 (en) * | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
AU2199500A (en) * | 1998-12-23 | 2000-07-31 | Alza Corporation | Gastric retention dosage form having multiple layers |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
CA2259730A1 (en) * | 1999-01-18 | 2000-07-18 | Bernard Charles Sherman | Sustained release tablets containing bupropion hydrochloride |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
CA2376202C (en) * | 1999-06-07 | 2008-11-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel preparation and administration form comprising an acid-labile active compound |
US7815590B2 (en) | 1999-08-05 | 2010-10-19 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
BR0007360A (pt) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Composição de liberação controlada |
MXPA02006367A (es) * | 1999-12-27 | 2002-11-29 | Kimberly Clark Co | Fibras que proporcionan entrega controlada de agente activo. |
MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
US8178150B2 (en) | 2000-02-22 | 2012-05-15 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US7892586B2 (en) | 2001-02-22 | 2011-02-22 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6730320B2 (en) * | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
DE10014588A1 (de) | 2000-03-27 | 2001-10-04 | Basf Ag | Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung |
IL151475A0 (en) | 2000-03-30 | 2003-04-10 | Bristol Myers Squibb Co | Beadlets containing stavudine |
US6306436B1 (en) * | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
US7056531B1 (en) * | 2000-05-04 | 2006-06-06 | Nature's Way Products, Inc. | Sustained release compositions for orally administered substances and methods |
US6488962B1 (en) * | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
US6720005B1 (en) * | 2000-07-07 | 2004-04-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Coated, platform-generating tablet |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20020197314A1 (en) | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
US20020192161A1 (en) * | 2001-04-10 | 2002-12-19 | Fahkreddin Jamali | Animal model for evaluating analgesics |
US20020187192A1 (en) * | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
JP2004537401A (ja) * | 2001-08-08 | 2004-12-16 | ブラウン ユニバーシティ リサーチ ファウンデーション | 疎水性薬物の微粉砕方法 |
IL160363A0 (en) * | 2001-08-16 | 2004-07-25 | Oregon State | Expandable gastric retention device |
US20040219186A1 (en) * | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
US20030060483A1 (en) * | 2001-09-24 | 2003-03-27 | Day Charles E. | Method of increasing pharmaceutical market |
US20040001886A1 (en) * | 2001-10-17 | 2004-01-01 | Dr. Reddy's Laboratories Limited | Stabilized pharmaceutical formulations containing amlodipine maleate |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
US20030147965A1 (en) * | 2001-12-10 | 2003-08-07 | Spherics, Inc. | Methods and products useful in the formation and isolation of microparticles |
TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
US7053029B2 (en) * | 2002-03-27 | 2006-05-30 | Kimberly-Clark Worldwide, Inc. | Use indicating soap |
AU2003245504A1 (en) * | 2002-06-14 | 2003-12-31 | Andrx Corporation | Pharmaceutical compositions for drugs having ph-dependentsolubility |
US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
GB0214013D0 (en) * | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
EP1539265B1 (en) * | 2002-08-13 | 2007-09-26 | Medtronic, Inc. | Active agent delivery system including a hydrophobic cellulose derivate |
CA2494186A1 (en) * | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery system including a poly(ethylene-co-(meth)acrylate), medical device, and method |
US20040033251A1 (en) * | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery system including a polyurethane, medical device, and method |
CA2495181A1 (en) * | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery system including a hydrophilic polymer, medical device, and method |
US20040086569A1 (en) * | 2002-08-13 | 2004-05-06 | Medtronic, Inc. | Active agent delivery systems, medical devices, and methods |
AU2003255874A1 (en) * | 2002-08-16 | 2004-03-03 | Orchid Health Care, A Division Of Orchid Chemicals And Pharmaceuticals Ltd. | Sustained release pharmaceutical composition of a cephalosporin antibiotic |
US20040033262A1 (en) * | 2002-08-19 | 2004-02-19 | Orchid Health Care | Sustained release pharmaceutical composition of a cephalosporin antibiotic |
US7960326B2 (en) * | 2002-09-05 | 2011-06-14 | Kimberly-Clark Worldwide, Inc. | Extruded cleansing product |
US20040126318A1 (en) * | 2002-09-12 | 2004-07-01 | Ehrenpreis Eli D. | Methods, formulations and kits for monitoring and diagnosing gastric emptying and gastroparesis, and formulations for determining gastrointestinal motility |
US20040086566A1 (en) * | 2002-11-04 | 2004-05-06 | Alpharma, Inc. | Waxy matrix dosage forms |
US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
NZ542303A (en) * | 2003-03-14 | 2008-12-24 | Nirmal Mulye | A process for preparing sustained release tablets |
SI2316456T1 (sl) | 2003-04-29 | 2017-10-30 | Orexigen Therapeutics, Inc. | Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion |
WO2004103291A2 (en) * | 2003-05-16 | 2004-12-02 | Eisai Co., Ltd. | Extended release compositions of proton pump inhibitor |
CA2675724C (en) * | 2003-06-16 | 2012-12-04 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US7554452B2 (en) * | 2003-07-18 | 2009-06-30 | Cary Cole | Ingestible tracking and locating device |
US8308682B2 (en) | 2003-07-18 | 2012-11-13 | Broncus Medical Inc. | Devices for maintaining patency of surgically created channels in tissue |
US8002740B2 (en) | 2003-07-18 | 2011-08-23 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
JP2006528185A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
US8313775B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
US8313776B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
CA2533165A1 (en) * | 2003-07-21 | 2005-01-27 | Bio-Dar Ltd. | Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
WO2005009199A2 (en) | 2003-07-30 | 2005-02-03 | Merrion Research I Limited | Process and machine for automated manufacture of gastro-retentive capsules |
WO2005014906A2 (en) * | 2003-08-07 | 2005-02-17 | Polymer Group, Inc. | Cleaning sheet with improved three-dimensional cleaning surface |
ATE454138T1 (de) | 2003-08-08 | 2010-01-15 | Biovail Lab Int Srl | Tablette mit modifizierter freisetzung von bupropion hydrochlorid |
WO2005016311A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
JP2007502294A (ja) | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
EP1684820A2 (en) * | 2003-08-13 | 2006-08-02 | Medtronic, Inc. | Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
WO2005018697A2 (en) * | 2003-08-13 | 2005-03-03 | Medtronic, Inc. | Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods |
EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
EP1658034A4 (en) * | 2003-08-29 | 2011-06-22 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
US20050053655A1 (en) * | 2003-09-05 | 2005-03-10 | Pharmaceutical Industry Technology And Development Center | Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same |
JP2007513869A (ja) | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
AU2004285533A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption |
US20080089933A1 (en) | 2006-10-16 | 2008-04-17 | Amir Alon | Device and method for reducing calorie intake |
US20070196396A1 (en) * | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
JP2008505124A (ja) | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
US8409167B2 (en) | 2004-07-19 | 2013-04-02 | Broncus Medical Inc | Devices for delivering substances through an extra-anatomic opening created in an airway |
CA2574912A1 (en) * | 2004-07-30 | 2006-02-02 | Merrion Research Ii Limited | Improved process and machine for automated manufacture of gastro-retentive devices |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性(biosynchronous)経皮的薬物送達 |
US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US20060068009A1 (en) * | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
MX2007005390A (es) * | 2004-11-05 | 2007-08-23 | Electronic Dietary Foods Inc | Degradacion controlada de polimeros expandibles en tratamiento de reduccion de volumen gastrico. |
US20060099262A1 (en) * | 2004-11-08 | 2006-05-11 | Biokey, Inc. | Methods and formulations for making controlled release oral dosage form |
US8586085B2 (en) * | 2004-11-08 | 2013-11-19 | Biokey, Inc. | Methods and formulations for making pharmaceutical compositions containing bupropion |
KR100670798B1 (ko) * | 2004-12-17 | 2007-01-17 | 한국전자통신연구원 | 데이터베이스 캐시 시스템 |
NZ556202A (en) * | 2005-01-04 | 2010-03-26 | Teikoku Pharma Usa Inc | Cooling topical patch preparation |
US8852083B2 (en) * | 2005-02-04 | 2014-10-07 | Uti Limited Partnership | Self-stabilized encapsulated imaging system |
US7829000B2 (en) * | 2005-02-25 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Core-shell solid freeform fabrication |
WO2006113568A2 (en) * | 2005-04-19 | 2006-10-26 | Alza Corporation | Controlled delivery dosage form of tramadol and gabapentin |
US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7919483B2 (en) | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
US7544373B2 (en) * | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
US7541347B2 (en) * | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
WO2007002597A2 (en) * | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
EP1915990A1 (en) * | 2005-07-15 | 2008-04-30 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation |
DE602005007205D1 (de) * | 2005-07-19 | 2008-07-10 | Ethypharm Sa | Gastroretentive Zusammensetzungen und Verfahren zur Herstellung |
US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
WO2007048219A2 (en) | 2005-09-09 | 2007-05-03 | Labopharm Inc. | Sustained drug release composition |
US20070093555A1 (en) * | 2005-10-24 | 2007-04-26 | Jutaro Shudo | Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same |
US20070092559A1 (en) * | 2005-10-24 | 2007-04-26 | Jinghua Yuan | Liquid dosage forms having enteric properties of delayed and then sustained release |
US20070092565A1 (en) * | 2005-10-25 | 2007-04-26 | Pharmascience Inc. | Gastric retention drug delivery system |
NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
PT1954241E (pt) * | 2005-11-28 | 2012-06-01 | Orexigen Therapeutics Inc | Formulação de zonisamida de libertação sustentada |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
BRPI0708842A2 (pt) * | 2006-03-28 | 2011-06-14 | Gelesis Inc | uso de materiais polimÉricos com outras substÂncias para aumento do desempenho |
JP2009532532A (ja) * | 2006-03-30 | 2009-09-10 | ジェレシス, インク. | バイオ用途用のスチレン−無水マレイン酸コポリマ及びそれらの製剤 |
US9011930B2 (en) | 2006-05-01 | 2015-04-21 | Zycal Bioceuticals Healthcare Company, Inc. | Nutritional supplement and use thereof |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
JP2009543886A (ja) * | 2006-07-19 | 2009-12-10 | スミスクライン・ビーチャム・コーポレイション | ガンマシンチグラフィー評価のために処方物を放射性標識する方法 |
US8703191B2 (en) * | 2006-07-25 | 2014-04-22 | Intelgenx Corp. | Controlled-release pharmaceutical tablets |
US7674479B2 (en) * | 2006-07-25 | 2010-03-09 | Intelgenx Corp. | Sustained-release bupropion and bupropion/mecamylamine tablets |
KR20150082689A (ko) | 2006-11-09 | 2015-07-15 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
KR101735466B1 (ko) | 2006-11-09 | 2017-05-15 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
WO2008074153A1 (en) * | 2006-12-18 | 2008-06-26 | Electronic Dietary Foods Inc. | Device for delivery of a substance |
US9205094B2 (en) | 2006-12-22 | 2015-12-08 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
CA2673485A1 (en) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | Gastric retention-type sustained-release levodopa preparation |
WO2008118369A2 (en) | 2007-03-22 | 2008-10-02 | Dendreon Corporation | Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity |
US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
CA2694602A1 (en) * | 2007-07-27 | 2009-02-05 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
US8789536B2 (en) | 2007-10-17 | 2014-07-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8303573B2 (en) | 2007-10-17 | 2012-11-06 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8707964B2 (en) * | 2007-10-31 | 2014-04-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US20090105561A1 (en) * | 2007-10-17 | 2009-04-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Medical or veterinary digestive tract utilization systems and methods |
US8808276B2 (en) * | 2007-10-23 | 2014-08-19 | The Invention Science Fund I, Llc | Adaptive dispensation in a digestive tract |
US8808271B2 (en) * | 2007-10-31 | 2014-08-19 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8109920B2 (en) * | 2007-10-31 | 2012-02-07 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US20090163894A1 (en) * | 2007-10-31 | 2009-06-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Medical or veterinary digestive tract utilization systems and methods |
US8333754B2 (en) * | 2007-10-31 | 2012-12-18 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US20090137866A1 (en) * | 2007-11-28 | 2009-05-28 | Searete Llc, A Limited Liability Corporation Of The State Delaware | Medical or veterinary digestive tract utilization systems and methods |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
AU2009281752B2 (en) * | 2008-08-15 | 2016-11-17 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders |
EP2349221A4 (en) * | 2008-10-08 | 2013-03-27 | Bioplus Life Sciences Pvt Ltd | DELIVERING MEDICATION DELIVERY SYSTEM |
PL2376077T3 (pl) | 2009-01-12 | 2017-10-31 | Biokier Inc | Kompozycja i sposób leczenia cukrzycy |
US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
AR076341A1 (es) | 2009-04-20 | 2011-06-01 | Elcelyx Therapeutics Inc | Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion |
US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
MX2012003459A (es) * | 2009-09-23 | 2012-05-22 | Biokier Inc | Composicion y metodo para el tratamiento de la diabetes. |
US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
EP2544666A2 (en) | 2010-03-09 | 2013-01-16 | Council of Scientific and Industrial Research | Gastroretentive, extended release composition of therapeutic agent |
US8581001B2 (en) | 2010-04-16 | 2013-11-12 | Codman & Shurtleff | Metformin-cysteine prodrug |
WO2011151708A1 (en) * | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
US20120045510A1 (en) * | 2010-08-18 | 2012-02-23 | Joel Waldman | Tablet sleeve for improved performance |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
BR112013009635A2 (pt) | 2010-10-19 | 2016-07-12 | Elcelyx Therapeutics Inc | terapias à base de ligante de receptor quimiossensorial |
US9850379B2 (en) | 2010-11-08 | 2017-12-26 | Naihong Li | Gels and hydrogels |
CA2991216C (en) | 2010-12-22 | 2020-04-28 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
US10195114B2 (en) * | 2012-11-19 | 2019-02-05 | Guill Tool & Engineering Co., Inc | Microlayer coextrusion to create a time-release drug substance delivery product |
BR112013017411B1 (pt) | 2011-01-07 | 2022-03-22 | Anji Pharma (Us) Llc | Uso de uma composição compreendendo metformina ou um sal da mesma |
US8722066B2 (en) | 2011-03-29 | 2014-05-13 | Primigenia, LLC | Devices and methods for weight control and weight loss |
US8709034B2 (en) | 2011-05-13 | 2014-04-29 | Broncus Medical Inc. | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
WO2012158553A2 (en) | 2011-05-13 | 2012-11-22 | Broncus Technologies, Inc. | Methods and devices for excision of tissue |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
WO2013078235A1 (en) | 2011-11-23 | 2013-05-30 | Broncus Medical Inc | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
DK3730132T3 (da) | 2012-06-06 | 2022-08-08 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko |
WO2013183058A2 (en) | 2012-06-07 | 2013-12-12 | Tulip Medical Ltd. | Expanded device |
EP3878445A3 (en) | 2013-06-05 | 2021-10-27 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
WO2015083171A1 (en) | 2013-12-05 | 2015-06-11 | Tulip Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
CN106573015B (zh) | 2014-06-11 | 2021-11-26 | 麻省理工学院 | 肠溶弹性体 |
US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
KR101897218B1 (ko) * | 2015-05-11 | 2018-09-10 | 주식회사 아모라이프사이언스 | 수용성 고분자를 이용한 세포 배양 지지체 |
EP3364946A4 (en) * | 2015-10-23 | 2019-06-26 | Lyndra, Inc. | STOMACH DISTRIBUTION SYSTEMS FOR DELAYED RELEASE OF THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE |
CA3008636C (en) * | 2015-12-22 | 2022-07-19 | Mccormick & Company, Incorporated | High integrity encapsulation product |
US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
WO2018064630A1 (en) | 2016-09-30 | 2018-04-05 | Lyndra, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
AU2018205529B2 (en) | 2017-01-06 | 2023-08-10 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
WO2018213588A1 (en) | 2017-05-17 | 2018-11-22 | Massachusetts Institute Of Technology | Tissue anchoring articles |
US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
CA3076330A1 (en) * | 2017-09-20 | 2019-03-28 | Lyndra, Inc. | Encapsulation of gastric residence systems |
CN111417620B (zh) | 2017-12-01 | 2023-08-25 | 奥特吉尼克斯制药公司 | 肌酸前药、其组合物以及使用方法 |
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
CA3086153A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
WO2019222570A1 (en) | 2018-05-17 | 2019-11-21 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
CN114191307A (zh) | 2020-09-17 | 2022-03-18 | 上海汉都医药科技有限公司 | 一种口腔滞留装置及其制备方法 |
WO2019223753A1 (zh) | 2018-05-23 | 2019-11-28 | 上海汉都医药科技有限公司 | 活性药物成分的控释系统及其制备方法 |
US11911513B2 (en) | 2018-05-23 | 2024-02-27 | Shanghai Wd Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
EP3836866A4 (en) * | 2018-08-15 | 2022-06-15 | Lyndra Therapeutics, Inc. | SYSTEMS FOR THE ENTERIC DELIVERY OF THERAPEUTIC AGENTS |
JP2022523121A (ja) | 2019-02-01 | 2022-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | 液体注入のためのシステムおよび方法 |
WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
US11541216B2 (en) | 2019-11-21 | 2023-01-03 | Massachusetts Institute Of Technology | Methods for manufacturing tissue interfacing components |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3786813A (en) * | 1972-12-27 | 1974-01-22 | Alza Corp | Drug delivery device with self actuated mechanism for retaining device in selected area |
US4207890A (en) * | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
US5002772A (en) * | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
DE69014513T2 (de) * | 1989-09-21 | 1995-05-24 | American Cyanamid Co | System des Typs "einmal täglich" zur gepulsten Minocyclinabgabe. |
TW209174B (ja) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5534263A (en) * | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
-
1998
- 1998-08-10 EP EP98938469A patent/EP1003476B1/en not_active Expired - Lifetime
- 1998-08-10 AU AU86992/98A patent/AU8699298A/en not_active Abandoned
- 1998-08-10 DE DE69828289T patent/DE69828289T2/de not_active Expired - Lifetime
- 1998-08-10 US US09/131,923 patent/US6120803A/en not_active Expired - Lifetime
- 1998-08-10 AT AT98938469T patent/ATE285226T1/de not_active IP Right Cessation
- 1998-08-10 JP JP2000506936A patent/JP2001527023A/ja active Pending
- 1998-08-10 WO PCT/US1998/016597 patent/WO1999007342A1/en active IP Right Grant
- 1998-08-10 PT PT98938469T patent/PT1003476E/pt unknown
- 1998-08-10 ES ES98938469T patent/ES2234139T3/es not_active Expired - Lifetime
-
2000
- 2000-07-13 US US09/615,110 patent/US6548083B1/en not_active Expired - Fee Related
- 2000-10-30 HK HK00106880A patent/HK1028196A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001527023A5 (ja) | ||
US8765177B2 (en) | Bioadhesive progressive hydration tablets | |
ES2234139T3 (es) | Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica. | |
CA2409999C (en) | Optical polymer mixtures for gastric retentive tablets | |
Acarturk | Mucoadhesive vaginal drug delivery systems | |
AU719170B2 (en) | Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids | |
ES2389729T3 (es) | Sistema de retención gástrica | |
US4851232A (en) | Drug delivery system with means for obtaining desirable in vivo release rate pattern | |
CA2417686C (en) | Manufacture of oral dosage forms delivering both immediate release and sustained release drugs | |
US4434153A (en) | Drug delivery system comprising a reservoir containing a plurality of tiny pills | |
US7405238B2 (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
JP2008503475A5 (ja) | ||
JP2535339B2 (ja) | 活性物質の制御速度制御用装置 | |
CA2355860A1 (en) | Dosage forms comprising porous particles | |
AU4818293A (en) | Pharmaceutical tablet capable of liberating one or more drugs at different release rates | |
CA2405508A1 (en) | Hydrophilic/lipophilic polymeric matrix dosage formulation | |
AU2002337974A1 (en) | Optimal polymer mixtures for gastric retentive tablets | |
JPH07507059A (ja) | アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形 | |
WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
WO2005060942A1 (en) | Extended release pharmaceutical composition of metformin | |
NO303862B1 (no) | Fremgangsmåte til fremstilling av en anordning for avgivelse av et nyttig middel | |
US20030064101A1 (en) | Floating osmotic device for controlled release drug delivery | |
WO2004084873A1 (en) | Oral delivery system comprising an antibacterial and an anti-inflammatory agent | |
EP1976488A2 (en) | Sustained release compositions of alfuzosin | |
JP4177227B2 (ja) | 薬物の経口投与用徐放性組成物 |